Oncology Drug– category –

From Part 1 through Part 5, we explored CDK7/8/9/12/13/11 and their roles in transcriptional regulation. In this final installment, we turn to BRD4, a pivotal co-regulator that interacts closely with CDKs and controls super-enhancer–driv...

In Part 4, we examined CDK12/13 and their role in DNA repair and synthetic lethality. Here in Part 5, we focus on CDK11, a kinase that has recently gained attention for its role as a pause-checkpoint regulator in transcription, preceding...

In Parts 1–3, we reviewed CDK7/8 and CDK9. Here in Part 4, we turn to CDK12 and CDK13, transcriptional kinases that stabilize elongation of long DNA repair genes. They serve as “guardians” of genome stability and represent key players in...

In Parts 1 and 2, we introduced CDK7 and CDK8 in transcription initiation. Here in Part 3, we focus on CDK9, the central kinase controlling the transition from paused RNA polymerase II (Pol II) to productive elongation. Among transcripti...

In Part 1, we reviewed the fundamentals of transcription and the CDK family. In this article, we focus on CDK7 and CDK8, two kinases that act at the transcriptional “starting line.” While both regulate initiation, their roles and drug di...

This series focuses on the transcriptional machinery as an emerging target for cancer therapy, highlighting CDK (Cyclin-Dependent Kinases) families involved in transcription and BRD4. While CDK4/6 inhibitors have already transformed onco...

This series will explore the latest drug discovery trends targeting the transcriptional machinery. In Part 1, we provide an introduction: what transcription is, how CDKs regulate it, and why transcriptional CDKs are emerging as hot targe...

What’s Next — GDF15 Blockade and the Era of Precise Phenotypes Our finale focuses on near-future therapies and trial design. Beyond “weight,” we target phenotype × mechanism and build evidence that actually changes care. 3 takeaways Dire...

What Works Today — Nutrition, Exercise, Anti-inflammation, and Current Drugs Part 5 is a how-to guide. We align home and clinic workflows and run nutrition, resistance exercise, inflammation/symptom control as a package. Medications are ...

What Breaks in CAC? — Human Evidence on Appetite, Metabolism, Fat & Muscle In Part 4 we look behind the scenes using human data: central appetite circuits, systemic metabolism, adipose tissue, and skeletal muscle. We map these mechan...

Making CAC Visible — Phenotyping with CT, Function, and PROs Part 3 is a practical guide to phenotyping in clinic. Combine CT body composition, simple functional tests, and patient-reported outcomes (PROs) to sort patients into actionabl...

Don’t Miss It — Home & Clinic Checklists + FAQs Part 2 is a hands-on template pack. Use these copy-and-paste formats for two-week home monitoring and quick clinic checks so patients, families, and clinicians can share the same langua...

What Is CAC? — The Disease You Can’t See by Weight Alone This is a “super-basic” primer for patients, families, and general readers. We minimize jargon and focus on signs you can notice at home and what to bring to clinic visits. Why wei...

Biliary tract cancer (BTC), encompassing intrahepatic and extrahepatic cholangiocarcinoma as well as gallbladder cancer, remains a highly lethal malignancy with limited treatment options. In 2025, Cancer Discovery published a landmark st...

Fewer Moves, Deeper Reach — Answering Plasticity, Diversity, and State Shifts This closing chapter weaves the series into design principles that tackle GBM’s plasticity (OPC/AC/MES transitions), intratumoral diversity, and therapy-driven...

Who Excels Where? — Country Strengths, Access Gaps, and Implementation Paths The same plan can reach very different depths depending on the country and center. This chapter maps global strengths across basic research, clinical neuro-onco...

Global Landscape — A Modality-by-Modality Development Map Building on seed (pre-CC), niche (microenvironment), mobility, plasticity, and composite diagnostics, this chapter surveys GBM development by therapeutic modality. We focus on des...

Seeing What Matters — Composite Diagnostics (Imaging × Transcriptome × CNV) Therapy moves only when we can answer “for whom, when, and what.” This chapter maps a beginner-friendly framework for composite diagnostics across imaging, trans...

Plasticity & Escape — A Gentle Guide to OPC/AC/MES State Transitions Why do single agents rarely suffice? Because GBM has plasticity—it can shift among OPC-like, AC-like, and MES-like faces. Let’s build intuition and turn it into a p...

The Moving Tumor — Intuitive Guide to ECM, Adhesion, and White-Matter Tract Invasion Why does GBM come back even after “maximal” surgery? This beginner-first chapter explains the mobility of GBM via ECM, adhesion signaling, and the highw...